Recent Updates
Recently added Catalysts
ELDN Positive Sentiment Score: 70/100

Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

Wednesday, February 8, 2023 1 min read
Key Takeaway: Eledon Pharmaceuticals is set to present at the SVB Securities Global Biopharma Conference on February 15, 2023, led by CEO David-Alexandre C. Gros. This event highlights the company's ongoing development efforts in targeting the CD40 Ligand pathway for potential treatments, particularly in organ transplants and autoimmune diseases. The webcast will be available for those who cannot attend the live session, demonstrating Eledon's commitment to transparency and investor engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eledon Pharmaceuticals is actively presenting at a notable industry conference.
  • The company's lead compound, tegoprubart, is positioned to target significant therapeutic areas.
  • The presentation signifies the company's engagement with the biopharma community.

Full Press Release Details

IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the upcoming SVB Securities Global Biopharma Conference on February 15, 2023, at 5:00 p.m. ET.
To register in advance for the presentation webcast, sign up here.
A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.
About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)
Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
stephen@gilmartinir.com
Source: Eledon Pharmaceuticals

Tags

Frequently Asked Questions

When is Eledon Pharmaceuticals presenting at the conference?

Eledon Pharmaceuticals will present on February 15, 2023, at 5:00 p.m. ET.

What is Eledon's lead compound in development?

Eledon's lead compound is tegoprubart, an anti-CD40L antibody.

What therapeutic areas does Eledon focus on?

Eledon targets treatments for organ transplant, autoimmune diseases, and ALS.

Where is Eledon Pharmaceuticals headquartered?

Eledon Pharmaceuticals is headquartered in Irvine, California.

How can I access the presentation replay?

The replay will be available on the Events page of Eledon's website.

Tags: ELDN Viatris Investor Conferences Healthcare Eledon Pharmaceuticals tegoprubart SVB Securities biopharma conference clinical stage
Last updated: Feb 8, 2023